CN1110485C - 1－芳基磺酰基、芳基(硫代)羰基－哒嗪子基衍生物及其制法 - Google Patents

1－芳基磺酰基、芳基(硫代)羰基－哒嗪子基衍生物及其制法 Download PDF

Info

Publication number
CN1110485C
CN1110485C CN96199481A CN96199481A CN1110485C CN 1110485 C CN1110485 C CN 1110485C CN 96199481 A CN96199481 A CN 96199481A CN 96199481 A CN96199481 A CN 96199481A CN 1110485 C CN1110485 C CN 1110485C
Authority
CN
China
Prior art keywords
hydrogen
diaza
compound
dichloro
phenanthrene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96199481A
Other languages
English (en)
Chinese (zh)
Other versions
CN1207091A (zh
Inventor
D·W·库姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of CN1207091A publication Critical patent/CN1207091A/zh
Application granted granted Critical
Publication of CN1110485C publication Critical patent/CN1110485C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN96199481A 1995-11-06 1996-10-10 1－芳基磺酰基、芳基(硫代)羰基－哒嗪子基衍生物及其制法 Expired - Fee Related CN1110485C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US790095P 1995-11-06 1995-11-06
US60/007,900 1995-11-06

Publications (2)

Publication Number Publication Date
CN1207091A CN1207091A (zh) 1999-02-03
CN1110485C true CN1110485C (zh) 2003-06-04

Family

ID=21728709

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96199481A Expired - Fee Related CN1110485C (zh) 1995-11-06 1996-10-10 1－芳基磺酰基、芳基(硫代)羰基－哒嗪子基衍生物及其制法

Country Status (17)

Country Link
JP (1) JP2000501073A (no)
KR (1) KR100360614B1 (no)
CN (1) CN1110485C (no)
AU (1) AU704507B2 (no)
BR (1) BR9611407A (no)
CZ (1) CZ286789B6 (no)
HU (1) HU225162B1 (no)
IL (1) IL124320A (no)
MX (1) MX9803605A (no)
NO (1) NO310460B1 (no)
NZ (1) NZ319979A (no)
PL (1) PL185618B1 (no)
RU (1) RU2175969C2 (no)
TW (1) TW460467B (no)
UA (1) UA48989C2 (no)
WO (1) WO1997017332A1 (no)
ZA (1) ZA969298B (no)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.MED.CHEM.VOL14,NO3 1971-01-01 H.HOLAVAJR.ETAL *

Also Published As

Publication number Publication date
AU704507B2 (en) 1999-04-22
BR9611407A (pt) 1999-12-28
CZ286789B6 (en) 2000-07-12
KR100360614B1 (ko) 2003-06-02
CZ138098A3 (cs) 1998-09-16
PL326669A1 (en) 1998-10-12
CN1207091A (zh) 1999-02-03
TW460467B (en) 2001-10-21
HU225162B1 (en) 2006-07-28
PL185618B1 (pl) 2003-06-30
JP2000501073A (ja) 2000-02-02
AU7263796A (en) 1997-05-29
NO982030D0 (no) 1998-05-05
IL124320A (en) 2001-10-31
HUP0201305A2 (hu) 2002-12-28
MX9803605A (es) 1998-09-30
NO310460B1 (no) 2001-07-09
HUP0201305A3 (en) 2003-02-28
NO982030L (no) 1998-06-23
IL124320A0 (en) 1998-12-06
NZ319979A (en) 1999-11-29
UA48989C2 (uk) 2002-09-16
ZA969298B (en) 1998-05-05
WO1997017332A1 (en) 1997-05-15
KR19990067340A (ko) 1999-08-16
RU2175969C2 (ru) 2001-11-20

Similar Documents

Publication Publication Date Title
CN1353717A (zh) 四环黄体酮受体调节剂化合物及其方法
CN1349531A (zh) 作为黄体酮受体激动剂的氰基吡咯类
CN1042537A (zh) 喹诺酮衍生物
JP2003523353A (ja) アルファ−２−アドレナリン受容体アンタゴニストとしての、１，３−二置換ピロリジン
CN1337958A (zh) 调节雌激素受体的化合物和方法
CN1126473A (zh) 化学组合物
CN1219170A (zh) 取代的1,2,3,4-四氢化萘衍生物
CN1228775A (zh) 作为时间生物学药物的苯并呋喃和苯并吡喃
CN1399633A (zh) 嘧啶衍生物
EP2265582B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CN85101761A (zh) 新型色胺衍生物的制备方法和应用
CN1073171A (zh) 喹啉衍生物、其制备方法及其在治疗中的应用
KR20010024087A (ko) 모노아민 옥시다제 억제제 및 ｈ5-ＨＴ1Ｂ 길항제 또는부분 작용제의 배합물
CN1278809A (zh) 取代的苯并二氢吡喃衍生物
CN1152874C (zh) 抗精神病的4-(1h-吲哚基-1-基)-1-取代哌啶衍生物
CN1293669A (zh) 苄基哌嗪基－和苄基哌啶基－乙酮衍生物、其制备方法及其用作多巴胺d 受体拮抗剂的用途
CN1147485C (zh) 用作5-ht-2c受体拮抗剂的二氢吲哚衍生物
CN1166623C (zh) 2-苯氧基苯胺类衍生物
CN1882564A (zh) 调节类香草素－1受体(vr1)功能的吲唑－3－酮及其类似物和衍生物
CN1110485C (zh) 1－芳基磺酰基、芳基(硫代)羰基－哒嗪子基衍生物及其制法
CN1259944A (zh) 选择性的雌激素受体调节剂用于治疗或预防前列腺癌及良性前列腺增生
CN1194983A (zh) 新的2－氨基－1,2－二氢化茚化合物其制备方法和药物组合物
CA2307114A1 (en) Arylpiperazines as serotonin reuptake inhibitors and 5-ht1d.alpha. antagonists
CN1429223A (zh) 新颖苯并呋喃衍生物
CN1321158A (zh) 作为药物的三环△3－哌啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee